3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension

Launched by SHENGJING HOSPITAL · Jul 24, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging method called three-dimensional magnetic resonance elastography (3D-MRE) to help doctors better understand and manage conditions related to cirrhosis and portal hypertension. Portal hypertension is a serious condition that can occur when there is increased pressure in the blood vessels of the liver, often resulting from cirrhosis, which is the scarring of the liver. The goal of the trial is to see if 3D-MRE can provide accurate predictions of liver pressure, which can help in creating personalized treatment plans for patients.

To be eligible for this trial, participants need to be over 18 years old, have a confirmed diagnosis of cirrhosis, and have undergone a 3D-MRE scan within a month before the measurement of liver pressure. They will also need to provide written consent to participate. The trial is currently recruiting participants of all genders, ranging from 65 to 74 years old. If you choose to participate, you can expect a non-invasive procedure that will help doctors learn more about your liver condition and how best to treat it.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. age \> 18 years old
• • 2. confirmed cirrhosis or ACLD (advanced chronic liver disease) (laboratory, imaging and clinical symptoms)
• • 3. with 3D-MRE within 1 month prior to HVPG measurement
• • 4. written informed consent
• Exclusion Criteria:
• • 1. any previous liver or spleen surgery
• • 2. liver cancer; chronic acute liver failure
• • 3. acute portal hypertension
• • 4. unreliable HVPG or 3D-MRE results due to technical reasons
• • 5. with liver interventional therapy between HVPG and 3D-MRE